GB2333957A - Medical use of composition comprising fatty acids - Google Patents
Medical use of composition comprising fatty acidsInfo
- Publication number
- GB2333957A GB2333957A GB9911472A GB9911472A GB2333957A GB 2333957 A GB2333957 A GB 2333957A GB 9911472 A GB9911472 A GB 9911472A GB 9911472 A GB9911472 A GB 9911472A GB 2333957 A GB2333957 A GB 2333957A
- Authority
- GB
- United Kingdom
- Prior art keywords
- combination
- fatty acids
- symptoms
- alleviating
- testing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
Landscapes
- Health & Medical Sciences (AREA)
- Emergency Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
A medicament for alleviating symptoms of multiple sclerosis is constituted by a combination of linolenic acid and linoleic acid (including their salts, esters, and amides) in specified percentage ratios. Such combination may include optionally an additional ingredient selected from C 8-18 saturated fatty acids, oleic acid and derivatives of these acids, in an amount which does not prevent the combination having potentially MS symptoms alleviating activity, as determined by testing such combination in an animal model. Pharmaceutical formulations and nutritional combinations are also described, as is a method for testing a chemical substance in an animal model for potential use in alleviating symptoms of multiple sclerosis.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IL11966196A IL119661A0 (en) | 1996-11-20 | 1996-11-20 | Medical use of composition comprising fatty acids |
PCT/IL1997/000366 WO1998021949A1 (en) | 1996-11-20 | 1997-11-13 | Medical use of composition comprising fatty acids |
Publications (2)
Publication Number | Publication Date |
---|---|
GB9911472D0 GB9911472D0 (en) | 1999-07-14 |
GB2333957A true GB2333957A (en) | 1999-08-11 |
Family
ID=11069504
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GB9911472A Withdrawn GB2333957A (en) | 1996-11-20 | 1997-11-13 | Medical use of composition comprising fatty acids |
Country Status (4)
Country | Link |
---|---|
AU (1) | AU4882397A (en) |
GB (1) | GB2333957A (en) |
IL (1) | IL119661A0 (en) |
WO (1) | WO1998021949A1 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL125731A (en) | 1998-08-11 | 2004-06-20 | Zvi Yehuda | Acylates which are products of neurotransmitters and essential fatty acids, pharmaceutical compositions containing them, use of such acylates in the manufacture of medicaments, and method for treating nervous diseases in non-human animals |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3993775A (en) * | 1974-04-25 | 1976-11-23 | John Williams | Immuno-suppressive agents |
US4386072A (en) * | 1981-06-26 | 1983-05-31 | Horrobin David F | Treatment of disorders of inflammation and immunity and disorders associated with smooth muscle spasm and compositions therefor |
US5194448A (en) * | 1989-11-30 | 1993-03-16 | Croda International Plc | Use of nervonic acid and long chain fatty acids for the treatment of demyelinating disorders |
-
1996
- 1996-11-20 IL IL11966196A patent/IL119661A0/en unknown
-
1997
- 1997-11-13 WO PCT/IL1997/000366 patent/WO1998021949A1/en active Application Filing
- 1997-11-13 GB GB9911472A patent/GB2333957A/en not_active Withdrawn
- 1997-11-13 AU AU48823/97A patent/AU4882397A/en not_active Abandoned
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3993775A (en) * | 1974-04-25 | 1976-11-23 | John Williams | Immuno-suppressive agents |
US4386072A (en) * | 1981-06-26 | 1983-05-31 | Horrobin David F | Treatment of disorders of inflammation and immunity and disorders associated with smooth muscle spasm and compositions therefor |
US5194448A (en) * | 1989-11-30 | 1993-03-16 | Croda International Plc | Use of nervonic acid and long chain fatty acids for the treatment of demyelinating disorders |
Also Published As
Publication number | Publication date |
---|---|
AU4882397A (en) | 1998-06-10 |
IL119661A0 (en) | 1997-02-18 |
GB9911472D0 (en) | 1999-07-14 |
WO1998021949A1 (en) | 1998-05-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HUT57541A (en) | Fungicidal compositions comprising substituted acrylic acid esters as active ingredient and process for producing the active ingredients | |
IL114447A0 (en) | Multiple unit pharmaceutical preparation | |
ATE15443T1 (en) | EDIBLE PHARMACEUTICAL COMPOSITIONS AND METHOD OF MANUFACTURE. | |
NZ515911A (en) | Implantable gel compositions and method of manufacture | |
ATE427925T1 (en) | PHENOXYCARBONIC ACID COMPOUNDS AND COMPOSITIONS FOR ADMINISTRATION OF ACTIVE INGREDIENTS | |
NO940277L (en) | Triglycerides and mixtures thereof | |
HUT47131A (en) | Process for producing steroid-5alpha-reductase inhibitors and pharmaceutical compositions comprising them as active ingredient | |
ATE73657T1 (en) | USE OF GAMMA-LINOLENIC ACID AND RELATED COMPOUNDS IN THE MANUFACTURE OF A MEDICINAL PRODUCT FOR THE TREATMENT OF ENDOMETRIOSIS. | |
NZ308293A (en) | Antibacterial-wound healing compositions comprising a pyruvate, antioxidant and fatty acids | |
HUT53634A (en) | Herbicides comprising aromatic carboxylic acid derivatives as active ingredient and process for producing the active ingredients | |
BG95786A (en) | PREPARATION FOR CONTROLLED RELEASE OF ACTIVE SUBSTANCES FOR RUMINANTS | |
EG17609A (en) | Process for preparation of therapeutic agents from derivatives of propoimic acid. | |
UA37259C2 (en) | Active substance for pharmaceutical compositions intended for treatment of dysfunctional metrorrhagia | |
NZ307055A (en) | Immunostimulating-wound healing compositions and methods for preparing and using same | |
DE69614375D1 (en) | DERMATOLOGICAL PREPARATION FOR THE TREATMENT OF ACTINIC KERATOSIS | |
EP0366480A3 (en) | Method and compositions for treating alzheimer's disease, related dementias & epilepsy | |
JPS5294433A (en) | Perfume blender | |
MY120521A (en) | Pharmaceutical microspheres of valproic acid for oral administration. | |
HUT52374A (en) | Process for producing pharmaceutical compositions | |
GB2333957A (en) | Medical use of composition comprising fatty acids | |
DE60027601D1 (en) | DRUG PREPARATION WITH CONTROLLED RELEASE CONTAINING TRAMADOL HYDROCHLORIDE | |
HUT61024A (en) | Process for producing 10(1-hydroxyethyl)-11-oxo-1-aza-tricyclo/7.2.0.0.3.8/undex-2-ene-2-carboxylic acid esters and pharmaceutical compositions comprising same as active ingredient | |
HUT51105A (en) | Pesticide comprising substituted acrylic acid ester derivatives as active ingredient and process for producing the active ingredients | |
DE69706241D1 (en) | Pharmaceutical composition for the treatment of leukemia containing 9-cis-retinoic acid alpha-tocopherol esters | |
GR3034803T3 (en) | Low-dose steroid tablets containing gallic acid esters as antioxidant agent, process for the manufacture of said tablets, and uses of said tablets |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WAP | Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1) |